BRIEF-Achillion announces initiation of patient dosing in phase 2 study of ACH-4471 By: Reuters: Company News April 06, 2017 at 06:25 AM EDT * Achillion announces initiation of patient dosing in phase 2 study of ACH-4471 for paroxysmal nocturnal hemoglobinuria Read More >> Related Stocks: Achison Inc